This is a subject blind, investigator and sponsor open, randomized study consisting of 2 parts. Up to 15 healthy subjects will be included in the study. In the first part of the study the test retest reliability of the radiotracer \[11C\] PF 04767135 binding in man will be assessed. In the second part of this study, using \[11C\] PF 04767135, kappa opioid receptor occupancy (RO) will be assessed in up to three cohorts of subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
12
Single dose of up to 30 mg PF-04455242, delivered in capsule.
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Overall kappa opioid receptor occupancy of PF 04455242.
Time frame: Study Day 1 and 2
Binding potential (BP) of [11C] PF 04767135.
Time frame: Study Day 1 and 2
Kappa opioid receptor occupancy of PF 04455242 at regions of interest in man.
Time frame: Study Day 1 and 2
Relationship between plasma PF 04455242 concentration and kappa opioid receptor occupancy (IC50).
Time frame: Study Day 1 and 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.